Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXG202 in nAMD
NCT07178249Phase 2Not yet recruiting
- Sponsor
- Hangzhou Jiayin Biotech
- Start
- Oct 2025
- Primary completion
- Feb 2028
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
01
Overview
Phase 2, open-label trial of EXG202 in neovascular age-related macular degeneration (NVAMD) (4 arms), sponsored by Hangzhou Jiayin Biotech. Primary endpoints: Safety and tolerability after EXG202 injection at 52 weeks and Preliminary Efficacy after EXG202 injection at 52 weeks. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
EXG202
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07178249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178249.